abstract |
Provided is a monoclonal antibody against programmed cell death factor 1 ligand (PDL-1) or an antigen-binding fragment thereof, the monoclonal antibody can specifically bind to PDL-1, and relieve the inhibition of PDL-1 on body immunity , thereby activating T lymphocytes. Also provided are pharmaceutical compositions and uses comprising the monoclonal antibodies. |